AUTL NASDAQ
Autolus Therapeutics plc
1W: -4.3%
1M: -20.5%
3M: +9.2%
YTD: -4.8%
1Y: +6.6%
3Y: -23.3%
5Y: -71.7%
$1.78
-0.07 (-3.78%)
Weekly Expected Move ±6.9%
$2
$2
$2
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$76M
+646.7% ▲
5Y CAGR: +113.2%
Gross Profit
-$21M
+83.9% ▲
Operating Income
-$281M
-16.6% ▼
Net Income
-$288M
-30.3% ▼
EPS (Diluted)
$-1.08
-24.1% ▼
EBITDA
-$281M
-20.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2M | $6M | $2M | $10M | $76M |
| YoY Growth | +862.8% | +165.8% | -72.6% | +496.0% | +646.7% |
| Cost of Revenue | $0 | $0 | $0 | $141M | $96M |
| Gross Profit | $2M | $6M | $2M | -$131M | -$21M |
| Gross Margin | 100.0% | 100.0% | 100.0% | -1293.5% | -27.8% |
| R&D Expenses | $111M | $117M | $130M | $158M | $118M |
| SG&A Expenses | $32M | $32M | $47M | $0 | $132M |
| Operating Expenses | $142M | $149M | $181M | $111M | $260M |
| Operating Income | -$140M | -$143M | -$180M | -$241M | -$281M |
| Operating Margin | -9314.8% | -2307.0% | -10583.1% | -2385.6% | -372.4% |
| Interest Expense | $1M | $9M | $45M | $9M | $37M |
| Income Before Tax | -$142M | -$149M | -$208M | -$219M | -$297M |
| Tax Expense | $58K | $272K | -$19K | $2M | -$9M |
| Net Income | -$142M | -$149M | -$208M | -$221M | -$288M |
| Net Margin | -9429.1% | -2403.0% | -12272.3% | -2180.5% | -380.5% |
| EPS (Diluted) | $-1.97 | $-1.57 | $-1.20 | $-0.87 | $-1.08 |
| EBITDA | -$132M | -$132M | -$157M | -$233M | -$281M |
| Shares Outstanding | 72M | 95M | 174M | 255M | 266M |